Mrna vaccines against sars-cov-2: advantages and caveats

Simple item page
dc.contributor.authorEchaide Górriz, Míriam
dc.contributor.authorChocarro de Erauso, Luisa
dc.contributor.authorBocanegra Gondán, Ana Isabel
dc.contributor.authorBlanco, Ester
dc.contributor.authorKochan, Grazyna
dc.contributor.authorEscors Murugarren, David
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.date.accessioned2023-08-11T06:50:30Z
dc.date.available2023-08-11T06:50:30Z
dc.date.issued2023
dc.date.updated2023-08-11T06:19:44Z
dc.description.abstractThe application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of 2021, millions of doses have been administered in several countries of North and South America and Europe. Many studies have confirmed the efficacy of these vaccines in a wide range of ages and in vulnerable groups of people against COVID-19. Nevertheless, the emergence and selection of new variants have led to a progressive decay in vaccine efficacy. Pfizer–BioNTech and Moderna developed updated bivalent vaccines—Comirnaty and Spikevax—to improve responses against the SARS-CoV-2 Omicron variants. Frequent booster doses with monovalent or bivalent mRNA vaccines, the emergence of some rare but serious adverse events and the activation of T-helper 17 responses suggest the need for improved mRNA vaccine formulations or the use of other types of vaccines. In this review, we discuss the advantages and limitations of mRNA vaccines targeting SARS-CoV-2 focusing on the most recent, related publications.en
dc.description.sponsorshipThe OncoImmunology group is funded by the Spanish Association against Cancer (AECC, PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (FIS PI17/02119, FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069); a Biomedicine Project grant from the Department of Health of the Government of Navarre (BMED 050-2019); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848166.en
dc.format.mimetypeapplication/pdfen
dc.identifier.citationEchaide, M., Chocarro De Erauso, L., Bocanegra, A., Blanco, E., Kochan, G., & Escors, D. (2023). Mrna vaccines against sars-cov-2: Advantages and caveats. International Journal of Molecular Sciences, 24(6), 5944. https://doi.org/10.3390/ijms24065944en
dc.identifier.doi10.3390/ijms24065944
dc.identifier.issn1661-6596
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/45919
dc.language.isoengen
dc.publisherMDPIen
dc.relation.ispartofInternational Journal of Molecular Sciences, 2023, 24, 5944en
dc.relation.projectIDinfo:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gobierno de Navarra//050-2019/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000013/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000033/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2019-000058/
dc.relation.publisherversionhttps://doi.org/10.3390/ijms24065944
dc.rights© 2023 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBNT162b2en
dc.subjectComirnatyen
dc.subjectMRNA vaccinesen
dc.subjectMRNA-1273en
dc.subjectMyocarditisen
dc.subjectSARS-CoV-2en
dc.subjectSpikevaxen
dc.subjectTh17 responseen
dc.subjectVariantsen
dc.titleMrna vaccines against sars-cov-2: advantages and caveatsen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublicationfe5c362e-3c0c-4edb-aa2e-0de27c815ad2
relation.isAuthorOfPublication.latestForDiscoveryfe5c362e-3c0c-4edb-aa2e-0de27c815ad2

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Echaide_mRNAVaccines.pdf
Size:
1009.77 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.78 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak
Investigaciones financiadas por la Unión Europea (OpenAire) - Europar Batasunak finantzatutako ikerketak (OpenAire)